

Rev03
Update: Dec,14,2021

DATASHEET

RANTES/CCL5, Human

Cat. No.: Z02832

Product Introduction

Species	Human
Protein Construction	CCL5 (Ser24-Ser91) Accession # P13501
Purity	> 98% as analyzed by SDS-PAGE > 98% as analyzed by HPLC
Endotoxin Level	< 1 EU/μg of protein by LAL method
Biological Activity	Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human peripheral blood monocytes is in a concentration range of 1.0-10.0 ng/ml.
Expression System	E. coli
Theoretical Molecular Weight	7.8 kDa
Formulation	Lyophilized from a 0.2 μm filtered solution in 20 mM PB, pH 7.4, 100 mM NaCl.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Background

Target Background : CCL5 or RANTES (acronym for Regulated upon Activation, Normal T cell Expressed and presumably Secreted), was initially discovered by subtractive hybridization as a transcript expressed in T cells but not B cells. Eosinophilchemotactic activities released by thrombinstimulated human platelets have also been purified and found to be identical to RANTES. Besides T cells and platelets, RANTES has been reported to be produced by renal tubular epithelium, synovial fibroblasts and selected tumor cells.

Synonyms : CCL-5; D17S136E; RANTES; SCYA5; SIS-delta; SISd; TCP228; eoCP; C-C motif chemokine ligand 5

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.